1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Inflammatory Pain - Pipeline Review, H1 2014

Inflammatory Pain - Pipeline Review, H1 2014

  • February 2014
  • -
  • Global Markets Direct
  • -
  • 174 pages

Inflammatory Pain - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Inflammatory Pain - Pipeline Review, H1 2014’, provides an overview of the Inflammatory Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Inflammatory Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Inflammatory Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Inflammatory Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Inflammatory Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Inflammatory Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Inflammatory Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Inflammatory Pain - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Inflammatory Pain Overview 10
Therapeutics Development 11
Pipeline Products for Inflammatory Pain - Overview 11
Pipeline Products for Inflammatory Pain - Comparative Analysis 12
Inflammatory Pain - Therapeutics under Development by Companies 13
Inflammatory Pain - Therapeutics under Investigation by Universities/Institutes 17
Inflammatory Pain - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Inflammatory Pain - Products under Development by Companies 22
Inflammatory Pain - Products under Investigation by Universities/Institutes 25
Inflammatory Pain - Companies Involved in Therapeutics Development 26
Boehringer Ingelheim GmbH 26
Kyowa Hakko Kirin Co., Ltd. 27
Shionogi and Co., Ltd. 28
AstraZeneca PLC 29
MedImmune, LLC 30
Merck and Co., Inc. 31
Takeda Pharmaceutical Company Limited 32
Glenmark Pharmaceuticals Ltd. 33
Pfizer Inc. 34
Evotec AG 35
Anavex Life Sciences Corp. 36
Nuvo Research Inc. 37
Zalicus Inc. 38
Array BioPharma Inc. 39
Neurim Pharmaceuticals Ltd 40
Pluristem Therapeutics Inc. 41
Upsher-Smith Laboratories, Inc. 42
Palau Pharma, S.A. 43
Grunenthal GmbH 44
AngioChem Inc. 45
Asahi Kasei Pharma Corp. 46
Hydra Biosciences, Inc. 47
NeurAxon, Inc. 48
Winston Pharmaceuticals, Inc. 49
CLL Pharma 50
MAKScientific, LLC 51
RaQualia Pharma Inc. 52
Relevare Pharmaceuticals Ltd. 53
NoNO, Inc. 54
Sunovion Pharmaceuticals Inc. 55
Adynxx, Inc. 56
Kareus Therapeutics, SA 57
Theralpha SAS 58
AnaMar AB 59
Istituto Italiano di Tecnologia 60
AbbVie Inc. 61
Aniona ApS 62
Periphagen Inc. 63
DiverDrugs, S.L. 64
Ziarco Pharma Ltd 65
A2M Pharma GmbH 66
AskAt Inc. 67
Biousian Biosystems, Inc. 68
Inflammatory Pain - Therapeutics Assessment 69
Assessment by Monotherapy Products 69
Assessment by Target 70
Assessment by Mechanism of Action 74
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
minocycline - Drug Profile 82
grapiprant - Drug Profile 83
AN-721 - Drug Profile 85
ZPL-3893787 - Drug Profile 86
Z-944 - Drug Profile 87
lidocaine - Drug Profile 88
S-120083 - Drug Profile 89
SYN-1002 - Drug Profile 90
Small Molecule To Antagonise P2X3 and P2X2/3 - Drug Profile 91
OX-MPI - Drug Profile 92
nNOS/iNOS - Drug Profile 93
HC-030031 - Drug Profile 94
zucapsaicin - Drug Profile 96
TrkA Program - Drug Profile 98
ANAVEX-1079 - Drug Profile 99
ANG-2002 - Drug Profile 100
AMAP-102 - Drug Profile 101
RQ-00000008 - Drug Profile 103
GBR-900 - Drug Profile 104
CDK9 Inhibitors - Drug Profile 105
Neu-P12 - Drug Profile 106
CNSB-002 - Drug Profile 107
CNSB-006 - Drug Profile 108
AK-106 - Drug Profile 109
Z-212 - Drug Profile 110
PLX Cells For Neuropathic And Inflammatory Pain - Drug Profile 111
THA-902 - Drug Profile 112
Conolidine - Drug Profile 113
AYX-3 - Drug Profile 114
Project MITRA - Drug Profile 115
Drug For Neuroscience - Drug Profile 116
Drugs Inhibiting SRC-ND2 For Neuropathic Pain And Inflammatory Pain - Drug Profile 117
Drug Targeting Cannabinoid Receptor - Drug Profile 118
DD-04107 - Drug Profile 119
AR-786 - Drug Profile 120
AZ-1 - Drug Profile 121
AZ-2 - Drug Profile 122
Small Molecule to Inhibit FAAH for Pain - Drug Profile 123
Drug For Inflammatory Pain - Drug Profile 124
ZJ-43 - Drug Profile 125
Compounds to inhibit Glutaminase for Pain - Drug Profile 127
THA-902 XL - Drug Profile 128
Next Generation Histamine H4 Antagonists - Drug Profile 129
MK-8825 - Drug Profile 130
MAK-2124 - Drug Profile 131
A-836339 - Drug Profile 132
SUN - Drug Profile 133
P2X3 Receptor Antagonist - Drug Profile 134
PNU-120596 - Drug Profile 135
AB-144 - Drug Profile 136
NET-END - Drug Profile 137
PF-3845 - Drug Profile 138
BIBN-4096BS - Drug Profile 139
CVIE - Drug Profile 140
imatinib mesylate - Drug Profile 141
URB-937 - Drug Profile 142
BBI-11008 - Drug Profile 143
A-1048400 - Drug Profile 144
NH-34 - Drug Profile 145
K-685 - Drug Profile 146
ET-1 - Drug Profile 147
GRTTA-2210 - Drug Profile 148
RO-656570 - Drug Profile 149
Nav 1.7 Blocker Program - Drug Profile 150
Nav1.8 Sodium Channel Blocker - Drug Profile 151
Neogenius Project - Drug Profile 152
Drug For Neuroscience 1 - Drug Profile 153
Drug Targeting Subtype Selective G Protein Coupled Receptor - Drug Profile 154
Inflammatory Pain - Recent Pipeline Updates 155
Inflammatory Pain - Dormant Projects 161
Inflammatory Pain - Discontinued Products 163
Inflammatory Pain - Product Development Milestones 164
Featured News and Press Releases 164
Appendix 169
Methodology 169
Coverage 169
Secondary Research 169
Primary Research 169
Expert Panel Validation 169
Contact Us 170
Disclaimer 170

List of Tables

Number of Products under Development for Inflammatory Pain, H1 2014 15
Number of Products under Development for Inflammatory Pain - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 18
Number of Products under Development by Companies, H1 2014 (Contd..1) 19
Number of Products under Development by Companies, H1 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2014 22
Comparative Analysis by Late Stage Development, H1 2014 23
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Development, H1 2014 25
Products under Development by Companies, H1 2014 26
Products under Development by Companies, H1 2014 (Contd..1) 27
Products under Development by Companies, H1 2014 (Contd..2) 28
Products under Investigation by Universities/Institutes, H1 2014 29
Inflammatory Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2014 30
Inflammatory Pain - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 31
Inflammatory Pain - Pipeline by Shionogi and Co., Ltd., H1 2014 32
Inflammatory Pain - Pipeline by AstraZeneca PLC, H1 2014 33
Inflammatory Pain - Pipeline by MedImmune, LLC, H1 2014 34
Inflammatory Pain - Pipeline by Merck and Co., Inc., H1 2014 35
Inflammatory Pain - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 36
Inflammatory Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014 37
Inflammatory Pain - Pipeline by Pfizer Inc., H1 2014 38
Inflammatory Pain - Pipeline by Evotec AG, H1 2014 39
Inflammatory Pain - Pipeline by Anavex Life Sciences Corp., H1 2014 40
Inflammatory Pain - Pipeline by Nuvo Research Inc., H1 2014 41
Inflammatory Pain - Pipeline by Zalicus Inc., H1 2014 42
Inflammatory Pain - Pipeline by Array BioPharma Inc., H1 2014 43
Inflammatory Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2014 44
Inflammatory Pain - Pipeline by Pluristem Therapeutics Inc., H1 2014 45
Inflammatory Pain - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 46
Inflammatory Pain - Pipeline by Palau Pharma, S.A., H1 2014 47
Inflammatory Pain - Pipeline by Grunenthal GmbH, H1 2014 48
Inflammatory Pain - Pipeline by AngioChem Inc., H1 2014 49
Inflammatory Pain - Pipeline by Asahi Kasei Pharma Corp., H1 2014 50
Inflammatory Pain - Pipeline by Hydra Biosciences, Inc., H1 2014 51
Inflammatory Pain - Pipeline by NeurAxon, Inc., H1 2014 52
Inflammatory Pain - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 53
Inflammatory Pain - Pipeline by CLL Pharma, H1 2014 54
Inflammatory Pain - Pipeline by MAKScientific, LLC, H1 2014 55
Inflammatory Pain - Pipeline by RaQualia Pharma Inc., H1 2014 56
Inflammatory Pain - Pipeline by Relevare Pharmaceuticals Ltd., H1 2014 57
Inflammatory Pain - Pipeline by NoNO, Inc., H1 2014 58
Inflammatory Pain - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014 59
Inflammatory Pain - Pipeline by Adynxx, Inc., H1 2014 60
Inflammatory Pain - Pipeline by Kareus Therapeutics, SA, H1 2014 61
Inflammatory Pain - Pipeline by Theralpha SAS, H1 2014 62
Inflammatory Pain - Pipeline by AnaMar AB, H1 2014 63
Inflammatory Pain - Pipeline by Istituto Italiano di Tecnologia, H1 2014 64
Inflammatory Pain - Pipeline by AbbVie Inc., H1 2014 65
Inflammatory Pain - Pipeline by Aniona ApS, H1 2014 66
Inflammatory Pain - Pipeline by Periphagen Inc., H1 2014 67
Inflammatory Pain - Pipeline by DiverDrugs, S.L., H1 2014 68
Inflammatory Pain - Pipeline by Ziarco Pharma Ltd, H1 2014 69
Inflammatory Pain - Pipeline by A2M Pharma GmbH, H1 2014 70
Inflammatory Pain - Pipeline by AskAt Inc., H1 2014 71
Inflammatory Pain - Pipeline by Biousian Biosystems, Inc., H1 2014 72
Assessment by Monotherapy Products, H1 2014 73
Number of Products by Stage and Target, H1 2014 76
Number of Products by Stage and Mechanism of Action, H1 2014 80
Number of Products by Stage and Route of Administration, H1 2014 83
Number of Products by Stage and Molecule Type, H1 2014 85
Inflammatory Pain Therapeutics - Recent Pipeline Updates, H1 2014 159
Inflammatory Pain - Dormant Projects, H1 2014 165
Inflammatory Pain - Dormant Projects (Contd..1), H1 2014 166
Inflammatory Pain - Discontinued Products, H1 2014 167

List of Figures
Number of Products under Development for Inflammatory Pain, H1 2014 15
Number of Products under Development for Inflammatory Pain - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 17
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Products, H1 2014 25
Assessment by Monotherapy Products, H1 2014 73
Number of Products by Top 10 Target, H1 2014 74
Number of Products by Stage and Top 10 Target, H1 2014 75
Number of Products by Top 10 Mechanism of Action, H1 2014 78
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 79
Number of Products by Top 10 Route of Administration, H1 2014 82
Number of Products by Stage and Top 10 Route of Administration, H1 2014 83
Number of Products by Top 10 Molecule Type, H1 2014 84
Number of Products by Stage and Top 10 Molecule Type, H1 2014 85

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in New Zealand - Forecast

  • December 2016
    71 pages
  • Therapy  

  • New Zealand  

View report >

Insulin Market in the US

  • December 2016
    8 pages
  • Insulin  

  • United States  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.